{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/","result":{"pageContext":{"chapter":{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment","depth":2,"htmlHeader":"<!-- begin field 746d3aa0-8aed-4bc9-974c-0d63d6c95759 --><h2>Scenario: Topical treatment</h2><!-- end field 746d3aa0-8aed-4bc9-974c-0d63d6c95759 -->","summary":"Covers the management of people receiving topical (skin) corticosteroids in primary care.","htmlStringContent":"<!-- begin item abcce840-02bc-4871-8c18-225e1b02265e --><!-- begin field 7e0d75e6-aa5c-4fa8-8524-acd900ab0cde --><p>From birth onwards.</p><!-- end field 7e0d75e6-aa5c-4fa8-8524-acd900ab0cde --><!-- end item abcce840-02bc-4871-8c18-225e1b02265e -->","topic":{"id":"091d926b-472d-55aa-b732-215f8299eb6e","topicId":"fe2967bf-dc0e-4dd2-903c-812a35c0d510","topicName":"Corticosteroids - topical (skin), nose, and eyes","slug":"corticosteroids-topical-skin-nose-eyes","lastRevised":"Last revised in September 2020","chapters":[{"id":"d7e6a05a-1ad6-5002-9e1d-418bb0509a7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"30c29984-be54-5cc7-b45b-ccea8330c500","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"01ed2c05-1414-51dd-85da-6ddc4bbc005d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"791cb5ff-e017-51d6-b7ee-cabacb293b82","slug":"changes","fullItemName":"Changes"},{"id":"110d5d5e-8e14-51d5-ab15-5afa0d551cf7","slug":"update","fullItemName":"Update"}]},{"id":"6481ae53-8731-5bbf-84bb-f9c18452558f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"746ed409-c3cc-5d5f-a043-6c7e517b0f61","slug":"goals","fullItemName":"Goals"},{"id":"40ab5ace-33b8-5a2c-a6bb-cbd7fe8ca07c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc1a105d-dd83-5e54-b930-588a3dbdb5cd","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f6a0228b-0765-5b1b-b1b7-25eca749a1ab","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"842d280b-d84c-5903-bbdb-3f4fe26412fc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"17589721-7493-5da3-8828-e2b4bec649b7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e1a50e32-af60-5677-ad61-93b4be058bdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e28586d8-7d65-5f08-a10b-d2d25b975112","slug":"definition","fullItemName":"Definition"},{"id":"58a9256e-a859-56a0-a7a3-946a224e6310","slug":"action-of-local-corticosteroids","fullItemName":"Action of local corticosteroids"},{"id":"8e053a89-aa32-5f75-aefc-61b421905b9d","slug":"availability","fullItemName":"Availability"}]},{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","fullItemName":"Management","slug":"management","subChapters":[{"id":"b60ad525-96a0-5836-9db8-d24fc5c18423","slug":"topical-treatment","fullItemName":"Scenario: Topical treatment"},{"id":"520275be-3f1d-5e10-8de2-5524f170f2ba","slug":"intranasal-corticosteroid-treatment","fullItemName":"Scenario: Intranasal corticosteroid treatment"},{"id":"f718a357-8e9a-50d8-ad33-87c1b4345715","slug":"eye-treatment","fullItemName":"Scenario: Eye treatment"}]},{"id":"ebd50a03-95ac-50a9-8a2d-4d615c9569bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0620ec75-3526-5198-b134-4f31d225ab30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2b03e883-8770-59d5-9965-04ffada0e471","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73e06218-1739-5de2-908f-ba65ba970168","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f813f700-2fb0-5989-90bd-2c2aa6dbb85a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3aa0e05-0446-53c0-9de1-2a8d2a9d1a70","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2a6ead30-5d09-5a96-b6d4-b673b755b98a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e78ffc84-8544-5685-8a35-65c8f05aac92","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1967c89c-d7ce-51d0-a539-3bf6738b65b4","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"6dcb1e43-0952-5b0a-94a9-1de0cd01d029","slug":"initiation","fullItemName":"Initiation","depth":3,"htmlHeader":"<!-- begin field 4c8806f0-e268-4bbe-8f0e-28f2a7712d4e --><h3>What should I consider when initiating topical corticosteroids?</h3><!-- end field 4c8806f0-e268-4bbe-8f0e-28f2a7712d4e -->","summary":null,"htmlStringContent":"<!-- begin item 714989ff-b037-4e62-8cff-0a8511ea2c5a --><!-- begin field 9c0b9e06-9888-446c-9693-52fadf887ca7 --><ul><li>Topical corticosteroids are effective and have few adverse effects if they are used appropriately.</li><li>The choice of topical corticosteroid depends on the condition being treated, the area of the body affected, and the age of the person.<ul><li>Mild eczema may only require a mild topical corticosteroid, whereas more potent topical corticosteroids may be required as part of the treatment strategy for psoriasis.<ul><li>Prescribe the least <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#potency\">potent</a> corticosteroid that relieves symptoms, and an <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#quantity-to-prescribe\">appropriate quantity</a>.</li><li>If the treatment is for a flare-up of disease activity, taper the treatment by using a less potent corticosteroid once the flare-up is under control.</li></ul></li><li>Areas where the skin is thin or flexural (such as the face, scrotum, groin, axillae, and submammary area) usually require a <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#potency\">mild or moderately potent</a> corticosteroid preparation.</li><li>Areas where the skin is thick, owing to either site (palms of the hands and soles of the feet) or from constant scratching (lichenification), usually require more <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#potency\">potent corticosteroid preparations.</a></li><li>Children and older people are more susceptible to the adverse effects of topical corticosteroids because they have a thinner epidermis. Older people also have decreased dermal collagen (owing to age and sun damage).</li></ul></li><li>Discuss the variety of <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#formulations\">formulations</a> available with the person.</li><li>Consider prescribing an emollient with the topical corticosteroid to moisturize the skin. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/prescribing-information/emollients/\">Emollients</a> in the CKS on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a>.</li></ul><!-- end field 9c0b9e06-9888-446c-9693-52fadf887ca7 --><!-- end item 714989ff-b037-4e62-8cff-0a8511ea2c5a -->","subChapters":[{"id":"d54e442c-f976-524a-9478-21723b934d6d","slug":"basis-for-recommendation-dc5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 57ca24d6-065a-4d40-85fc-694b07fa54b2 --><h4>Basis for recommendation</h4><!-- end field 57ca24d6-065a-4d40-85fc-694b07fa54b2 -->","summary":null,"htmlStringContent":"<!-- begin item dc52e3ff-5ec5-4562-a8f8-87946a06b0a1 --><!-- begin field 1dfd10f5-7faf-49a1-bf19-bf1d96ada040 --><p>These recommendations are based on expert opinion in narrative reviews <em>Topical steroids for skin disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Coulson, 1996</a>], <em>Guidelines of care for the management of psoriasis and psoriatic arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>], and <em>Choosing topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>]; the National Institute for Health and Care Excellence (NICE) guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2017</a>]; the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>]; and the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 1dfd10f5-7faf-49a1-bf19-bf1d96ada040 --><!-- end item dc52e3ff-5ec5-4562-a8f8-87946a06b0a1 -->","subChapters":[]}]},{"id":"876551df-5059-54fa-8c44-e6c5e2638854","slug":"length-of-treatment","fullItemName":"Length of treatment","depth":3,"htmlHeader":"<!-- begin field 1f0a665f-fde0-4bcd-9250-2131bb0fcafd --><h3>How long can I prescribe topical corticosteroids for?</h3><!-- end field 1f0a665f-fde0-4bcd-9250-2131bb0fcafd -->","summary":null,"htmlStringContent":"<!-- begin item 4d7555c6-6e3b-436b-8401-050e57f166cb --><!-- begin field 4d08d02c-c353-4d5d-b664-e89a90ae4627 --><ul><li>The length of treatment depends on the condition being treated — where possible treatment with topical corticosteroids should be intermittent to treat exacerbations of eczema or to reduce the size and thickness of plaques in psoriasis. </li><li>If symptoms do not improve 3–7 days after initiating a topical corticosteroid, reassess the condition and consider other potential causes: <ul><li><strong>Infection </strong>— such as impetigo, herpes simplex, or tinea corporis, which can be worsened by topical corticosteroids. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/impetigo/\">Impetigo</a>, <a class=\"topic-reference external-reference\" href=\"/topics/herpes-simplex-genital/\">Herpes simplex - genital</a>, <a class=\"topic-reference external-reference\" href=\"/topics/herpes-simplex-oral/\">Herpes simplex - oral</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-body-groin/\">Fungal skin infection - body and groin</a> for information on further management. </li><li><strong>Hypersensitivity reaction </strong>— consider switching to a corticosteroid with a different active ingredient or refer the person to a dermatologist if suspected hypersensitive reactions have occurred on multiple occasions. </li><li><strong>Non-adherence </strong>— this could be due to concerns about the safety of corticosteroids. Reassure the person that adverse effects are rare when topical corticosteroids are applied thinly to the affected areas only, and no more frequently than twice daily.</li><li><strong>Tolerance </strong>— consider switching to another topical corticosteroid of the same <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#potency\">potency</a>.</li></ul></li><li><strong>In people with psoriasis:</strong><ul><li>Arrange a review 4 weeks after starting a new topical treatment in adults, and 2 weeks after starting a new topical treatment in children. </li><li>Offer a review at least annually for adults using intermittent or short-term courses of potent or very potent topical corticosteroids, and for children using topical corticosteroids of any potency to assess for steroid atrophy and other adverse effects. <ul><li>More frequent monitoring is required for people using topical corticosteroids in intertriginous areas, on the face and neck, or under occlusion as adverse effects due to increased systemic absorption are more likely. </li></ul></li><li>Very potent corticosteroids should not be used continuously at any site for more than 4 weeks.<ul><li>Where a longer duration is required, consider seeking specialist advice, and monitor the person more frequently to detect possible <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#adverse-effects\">adverse effects</a> early.</li><li>Once symptoms improve, gradually taper down to a less potent topical corticosteroid to avoid a relapse of the condition. </li></ul></li><li>Potent corticosteroids should not be used continuously at any site for longer than 8 weeks. </li><li>Aim for a break of 4 weeks between courses of treatment with potent or very potent corticosteroids. </li></ul></li><li><strong>In people with eczema:</strong><ul><li>Treatment is generally short term (3–7 days) to control flares, and for up to 2 weeks in moderate to severe disease. </li><li>If using moderate or potent preparations for flares in vulnerable sites, such as axillae and groin, limit use to short periods (7–14 days).</li><li>Consider treating problem areas with topical corticosteroids for 2 consecutive days per week to prevent flares, instead of treating flares as they arise, in people with frequent flares. <ul><li>Review people receiving intermittent treatment every 3–6 months depending on the potency and site of application.</li></ul></li></ul></li><li>Once a clinical response has been seen, long-term topical corticosteroid treatment should be <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#withdrawal\">withdrawn</a> gradually in a stepwise manner.</li><li>For more information on managing eczema and psoriasis, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a> and <a class=\"topic-reference external-reference\" href=\"/topics/psoriasis/\">Psoriasis</a>.</li></ul><!-- end field 4d08d02c-c353-4d5d-b664-e89a90ae4627 --><!-- end item 4d7555c6-6e3b-436b-8401-050e57f166cb -->","subChapters":[{"id":"ce6b4df0-a93a-5384-ac69-d3020f5a1cec","slug":"basis-for-recommendation-e72","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field bc32e284-fd9f-4cd1-90b1-9d7f9bce87b6 --><h4>Basis for recommendation</h4><!-- end field bc32e284-fd9f-4cd1-90b1-9d7f9bce87b6 -->","summary":null,"htmlStringContent":"<!-- begin item e728c565-4332-4797-a62a-5238530cb2e6 --><!-- begin field e631e7d9-fb51-4414-9912-7880308e3f65 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2017</a>] and <em>Atopic eczema in under 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2007</a>]; the Scottish Intercollegiate Guidelines Network (SIGN) guideline<em> Management of atopic eczema in primary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SIGN, 2011</a>]; the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>]; and expert opinion in narrative reviews <em>Guidelines of care for the management of psoriasis and psoriatic arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>] and <em>Guidance on the diagnosis and clinical management of atopic eczema </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Baron, 2012</a>].</p><h5>Monitoring</h5><ul><li>The recommendation to monitor people more frequently if they are using topical corticosteroids in intertriginous areas, on the face or neck, or under occlusion is pragmatic and what CKS considers good medical practice, as adverse effects are more likely due to increased systemic absorption.  </li></ul><h5>Length of treatment</h5><ul><li>The recommendations on length of treatment are based on the MeReC bulletin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>], the NICE guidelines for psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2017</a>] and eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2007</a>], and expert opinion in a narrative review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Baron, 2012</a>]. </li><li>The Australian College of Dermatologists <em>Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement</em> advises that there is no requirement for intervals without therapy — the topical corticosteroid should be applied to all inflamed skin until eczema is cleared [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Mooney, 2015</a>]. </li></ul><!-- end field e631e7d9-fb51-4414-9912-7880308e3f65 --><!-- end item e728c565-4332-4797-a62a-5238530cb2e6 -->","subChapters":[]}]},{"id":"41dfbca2-f006-515d-af2f-0f1a7f05ca91","slug":"potency","fullItemName":"Potency","depth":3,"htmlHeader":"<!-- begin field bad3a6f5-26a0-4cbc-958e-861bf8a73e66 --><h3>What potency of topical corticosteroids should I prescribe?</h3><!-- end field bad3a6f5-26a0-4cbc-958e-861bf8a73e66 -->","summary":null,"htmlStringContent":"<!-- begin item 30f839a5-9ee0-4141-8786-fdfc171a890c --><!-- begin field f5e66272-ea8a-46e7-9309-71231d7f1515 --><ul><li>Topical corticosteroids are available in four potencies: mildly potent, moderately potent, potent, and very potent (see Table 1 for more details).<ul><li>The potency of a topical corticosteroid is determined by the amount of vasoconstriction it produces and the degree to which it inhibits inflammation.</li><li>Prescribe the least potent preparation that is effective, and avoid dilution if possible. </li><li>Application of corticosteroid immediately on top of, or before, an emollient may dilute the product and transfer corticosteroid to areas that do not require treatment. For information on the application of corticosteroids and emollients together, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#information-advice\">Information and advice</a>.</li></ul></li></ul><p><strong>Table 1.</strong> Topical corticosteroids listed by potency class.</p><table data-table-id=\"b8ace3bc-ecf5-45ff-b5ad-acce014f43cf\"><thead><tr><th>Potency class</th><th>Non-proprietary names and strengths</th><th>Proprietary names*</th><th>Formulations</th></tr></thead><tbody><tr><td>Mild</td><td>Hydrocortisone 0.1%, 0.5%, 1.0%, 2.5%</td><td>Dioderm, Mildison, Synalar 1 in 10 dilution</td><td>Cream and ointment</td></tr><tr><td rowspan=\"5\">Moderate</td><td>Alclometasone dipropionate 0.05%</td><td>Modrasone</td><td>Cream and ointment</td></tr><tr><td>Betamethasone valerate 0.025%</td><td>Betnovate-RD</td><td>Cream and ointment</td></tr><tr><td>Clobetasone butyrate 0.05%</td><td>Eumovate</td><td>Cream and ointment</td></tr><tr><td>Fluocinolone acetonide 0.00625%</td><td>Synalar 1 in 4 dilution</td><td>Cream and ointment</td></tr><tr><td>Fludroxycortide 0.0125%</td><td>Haelan</td><td>Cream, ointment, and tape</td></tr><tr><td rowspan=\"9\">Potent</td><td>Beclometasone dipropionate 0.025%</td><td>Generic</td><td>Cream and ointment</td></tr><tr><td>Betamethasone dipropionate 0.05%</td><td>Diprosone</td><td>Cream, ointment, and lotion</td></tr><tr><td>Betamethasone valerate 0.1%</td><td>Betnovate</td><td>Cream, ointment, lotion, scalp application, and foam </td></tr><tr><td>Diflucortolone valerate 0.1%</td><td>Nerisone</td><td>Cream, ointment, and oily cream</td></tr><tr><td>Fluocinolone acetonide 0.025%</td><td>Synalar</td><td>Cream, ointment, and gel</td></tr><tr><td>Fluocinonide 0.05%</td><td>Metosyn</td><td>Cream and ointment</td></tr><tr><td>Fluticasone propionate 0.05%</td><td>Cutivate</td><td>Cream </td></tr><tr><td>Hydrocortisone butyrate 0.1%</td><td>Locoid</td><td>Cream, ointment, and scalp application</td></tr><tr><td>Mometasone furoate 0.1%</td><td>Elocon</td><td>Cream, ointment, and scalp application</td></tr><tr><td rowspan=\"2\">Very potent</td><td>Clobetasol propionate 0.0525%</td><td>Dermovate, Clarelux</td><td>Cream, ointment, scalp application and foam</td></tr><tr><td>Diflucortolone valerate 0.3%</td><td>Nerisone Forte</td><td>Ointment and oily cream</td></tr><tr><td colspan=\"4\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].  *Note: generic products may also be available for some of these products.</td></tr></tbody></table><!-- end field f5e66272-ea8a-46e7-9309-71231d7f1515 --><!-- end item 30f839a5-9ee0-4141-8786-fdfc171a890c -->","subChapters":[{"id":"e9444834-4f60-5f31-a45f-ba548ab1c109","slug":"basis-for-recommendation-6fb","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8c3858b3-4fe6-451b-8c95-83038fc942b4 --><h4>Basis for recommendation</h4><!-- end field 8c3858b3-4fe6-451b-8c95-83038fc942b4 -->","summary":null,"htmlStringContent":"<!-- begin item 6fb3249e-105b-45c5-abd5-9d3595483722 --><!-- begin field e25b6100-32ef-4507-8764-ea93eccddba0 --><p>This information is based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>], the <em>British National Formulary </em>(BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>], and the National Institute for Health and Care Excellence (NICE) technology appraisal <em>Frequency of application of topical corticosteroids for atopic eczema </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2004</a>]. </p><!-- end field e25b6100-32ef-4507-8764-ea93eccddba0 --><!-- end item 6fb3249e-105b-45c5-abd5-9d3595483722 -->","subChapters":[]}]},{"id":"0fa018a3-6dc4-585d-b996-4f91f3ca86ce","slug":"formulations","fullItemName":"Formulations","depth":3,"htmlHeader":"<!-- begin field 1f298af6-c2a5-49e4-831b-7d8f6d9f82b7 --><h3>What formulation of topical corticosteroids should I prescribe?</h3><!-- end field 1f298af6-c2a5-49e4-831b-7d8f6d9f82b7 -->","summary":null,"htmlStringContent":"<!-- begin item b1b41362-7958-4866-9c4b-41e6348f5ce2 --><!-- begin field 27418074-4948-4bb2-963a-937431fba6bd --><ul><li>Topical corticosteroids are available in several formulations, including creams, ointments, lotions, gels, tapes, mousses, and solutions.</li><li>The choice of formulation depends on the condition being treated, its severity and location, cosmetic acceptability, and the person's preference. </li><li><strong>Solutions</strong><ul><li>Solutions are low viscosity, alcohol- or water-based liquids.</li><li>They are easy to apply and are non-greasy.</li><li>They are very drying if alcohol is the base, and can sting sore skin.</li></ul></li><li><strong>Lotions</strong><ul><li>Lotions are similar to solutions, but thicker.</li><li>They are useful for treating large or hairy areas and contain alcohol, which has a drying effect on exudative lesions. </li></ul></li><li><strong>Creams</strong><ul><li>Creams are thicker than lotions and are suitable for moist or weepy lesions.</li><li>Creams are generally less potent than ointments with the same active ingredient.  </li><li>They are moisturizing without being greasy. Many people prefer them, especially for use on the face and palms of the hands.</li></ul></li><li><strong>Ointments</strong><ul><li>Ointments are preferred for dry, lichenified, or scaly conditions, or where a more occlusive effect is required. </li><li>The occlusive effects can increase the penetration of the steroid. </li><li>They have a more prolonged emollient effect and tend to increase the potency of the corticosteroid. </li><li>They are less likely to cause irritation as they are usually preservative free. </li></ul></li><li><strong>Gels and mousses</strong><ul><li>Gels are thicker than solutions, and can be drying.</li><li>Mousses are stable, non-greasy foams.</li><li>Gels and mousses can be useful for scalp conditions.</li></ul></li><li><strong>Tapes and bandages</strong><ul><li>Potent and very potent topical corticosteroids used under occlusion should be under specialist supervision, used for only a short period of time, and for areas of very thick skin (such as the palms of the hands and soles of the feet).<ul><li>Occlusive polythene or hydrocolloid dressings increase the absorption of the corticosteroid and the risk of adverse effects.</li></ul></li></ul></li><li><strong>Compound preparations </strong>contain other substances such as:<ul><li>Antibacterials and antifungals — for infected skin. </li><li>Salicylic acid, calcipotriol, or coal tar — for psoriasis and other dry skin conditions.<ul><li>Some of these substances (for example urea and salicylic acid) may increase the penetration of the corticosteroid.</li></ul></li></ul></li></ul><!-- end field 27418074-4948-4bb2-963a-937431fba6bd --><!-- end item b1b41362-7958-4866-9c4b-41e6348f5ce2 -->","subChapters":[{"id":"0c86c3be-ae86-5ab9-838b-ad6cb149ecd7","slug":"basis-for-recommendation-340","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ff496d3b-9eed-4387-bf14-1db18247b30f --><h4>Basis for recommendation</h4><!-- end field ff496d3b-9eed-4387-bf14-1db18247b30f -->","summary":null,"htmlStringContent":"<!-- begin item 340169e9-8e21-418f-87fc-7cd693c612bf --><!-- begin field d1cf1c43-ea38-409b-afbc-50df2ac6ef91 --><p>This information is based on the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>]; the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>]; the National Institute for Health and Care Excellence and (NICE) guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2017</a>]; and expert opinion in narrative reviews <em>Topical steroids for skin disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Coulson, 1996</a>], <em>Guidelines of care for the management of psoriasis </em><em>and psoriatic arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>], and <em>Choosing topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>].</p><!-- end field d1cf1c43-ea38-409b-afbc-50df2ac6ef91 --><!-- end item 340169e9-8e21-418f-87fc-7cd693c612bf -->","subChapters":[]}]},{"id":"bfe230f7-78e3-5a61-8d43-858a0736d47c","slug":"application","fullItemName":"Application","depth":3,"htmlHeader":"<!-- begin field e4296798-1cef-4121-b2ef-77ee56a870d1 --><h3>How should topical corticosteroids be applied?</h3><!-- end field e4296798-1cef-4121-b2ef-77ee56a870d1 -->","summary":null,"htmlStringContent":"<!-- begin item da14da63-9354-44dd-8ecc-1d2ba0d9c7e9 --><!-- begin field 6f4d7eb9-17c2-4f2f-bb34-8f818e80ff70 --><ul><li>A thin layer of topical corticosteroid should be applied once or twice daily, adjusting the potency to control symptoms. For many conditions, once daily application is usually sufficient. Increase to twice daily application only if the condition does not respond adequately. <ul><li>Avoid the use of the phrase 'use sparingly' to avoid undertreatment.</li></ul></li><li>Topical corticosteroids should typically be used in bursts of 3–7 days in order to achieve control. Once a clinical response is seen, <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#withdrawal\">withdraw</a> the corticosteroid gradually. </li><li>If an emollient is also being used, advise the person to wait 20–30 minutes between applications. </li><li>Most products are supplied with an information leaflet specifying the number of fingertip units (FTUs) needed to treat specific body areas.<ul><li>One FTU is the length of cream or ointment expelled from a tube with a standard 5 mm diameter nozzle equivalent to the distance from the tip of the adult index finger to the first crease. One FTU is about 500 mg and is sufficient to treat a skin area about twice that of the flat of the hand with the fingers together.</li></ul></li><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#fingertip-units-ftus-for-adults\">Fingertip units (FTUs) for adults</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#fingertip-units-ftus-for-children\">Fingertip units (FTUs) for children</a> for the approximate amount of topical corticosteroid that should be applied to different areas of the body.</li></ul><!-- end field 6f4d7eb9-17c2-4f2f-bb34-8f818e80ff70 --><!-- end item da14da63-9354-44dd-8ecc-1d2ba0d9c7e9 -->","subChapters":[{"id":"ce8aecb4-c328-51a4-83f8-9982d183bf0d","slug":"fingertip-units-ftus-for-children","fullItemName":"Fingertip units (FTUs) for children","depth":4,"htmlHeader":"<!-- begin field 21e224a9-210b-4cb0-9791-a7a700edd42e --><h4>Fingertip units (FTUs) for children</h4><!-- end field 21e224a9-210b-4cb0-9791-a7a700edd42e -->","summary":null,"htmlStringContent":"<!-- begin item 88bf764a-41f8-4064-b72c-a7a700edd191 --><!-- begin field 32f32bbd-ae0d-4f2e-a82b-a7a700edd42e --><ul><li>The fingertip unit (FTU) is measured on an adult index finger.</li><li>The approximate amount of topical corticosteroid that should be applied to children, for each area of the body, is listed in Table 2.</li></ul><p><strong>Table 2.</strong> Amount of topical preparation (in FTUs) for different areas of a child's body.</p><table data-table-id=\"3c778607-703c-4f44-b6cd-acce014f7b3a\"><thead><tr><th colspan=\"1\">Age of child</th><th colspan=\"1\">Entire face and neck</th><th colspan=\"1\">Entire arm and hand</th><th colspan=\"1\">Entire leg and foot</th><th colspan=\"1\">Entire front of chest and abdomen</th><th colspan=\"1\">Entire back including buttocks</th></tr></thead><tbody><tr><td colspan=\"1\">3–12 months</td><td colspan=\"1\">1</td><td colspan=\"1\">1</td><td colspan=\"1\">1.5</td><td colspan=\"1\">1</td><td colspan=\"1\">1.5</td></tr><tr><td colspan=\"1\">1–2 years</td><td colspan=\"1\">1.5</td><td colspan=\"1\">1.5</td><td colspan=\"1\">2</td><td colspan=\"1\">2</td><td colspan=\"1\">3</td></tr><tr><td colspan=\"1\">3–5 years</td><td colspan=\"1\">1.5</td><td colspan=\"1\">2</td><td colspan=\"1\">3</td><td colspan=\"1\">3</td><td colspan=\"1\">3.5</td></tr><tr><td colspan=\"1\">6–10 years</td><td colspan=\"1\">2</td><td colspan=\"1\">2.5</td><td colspan=\"1\">4.5</td><td colspan=\"1\">3.5</td><td colspan=\"1\">5</td></tr><tr><td colspan=\"6\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Long, 1998</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>]</td></tr></tbody></table><!-- end field 32f32bbd-ae0d-4f2e-a82b-a7a700edd42e --><!-- end item 88bf764a-41f8-4064-b72c-a7a700edd191 -->","subChapters":[]},{"id":"870b3ff7-5191-517a-a687-f09fe6096cfe","slug":"fingertip-units-ftus-for-adults","fullItemName":"Fingertip units (FTUs) for adults","depth":4,"htmlHeader":"<!-- begin field be7b108e-70c9-4981-a2f2-a74a00aa8529 --><h4>Fingertip units (FTUs) for adults</h4><!-- end field be7b108e-70c9-4981-a2f2-a74a00aa8529 -->","summary":null,"htmlStringContent":"<!-- begin item 62a85c90-fe82-4ff3-9175-a74a00aa84fa --><!-- begin field 87b43142-a8f9-40ed-840d-a74a00aa8529 --><ul><li>The approximate amount of topical corticosteroid that should be applied to adults, for each area of the body, is listed in Table 3.</li></ul><p><strong>Table 3.</strong> Amount of topical preparation (in FTUs) for different areas of an adult's body.</p><table data-table-id=\"8af1d93f-9cee-4be1-b611-acce014f7c87\"><thead><tr><th scope=\"col\">Body area</th><th scope=\"col\">Number of FTUs</th></tr></thead><tbody><tr><td>Scalp</td><td>3</td></tr><tr><td>Face and neck</td><td>2.5</td></tr><tr><td>One hand (front and back including fingers)</td><td>1</td></tr><tr><td>One arm (including entire hand)</td><td>4</td></tr><tr><td>Elbows (large plaque)</td><td>1</td></tr><tr><td>Both soles of feet</td><td>1.5</td></tr><tr><td>One foot (dorsum and sole) including toes</td><td>1.5</td></tr><tr><td>One leg (including entire foot)</td><td>8</td></tr><tr><td>Buttocks</td><td>4</td></tr><tr><td>Knees (large plaque)</td><td>1</td></tr><tr><td>Trunk (front)</td><td>8</td></tr><tr><td>Trunk (back)</td><td>8</td></tr><tr><td>Genitalia</td><td>0.5</td></tr><tr><td colspan=\"2\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>]</td></tr></tbody></table><!-- end field 87b43142-a8f9-40ed-840d-a74a00aa8529 --><!-- end item 62a85c90-fe82-4ff3-9175-a74a00aa84fa -->","subChapters":[]},{"id":"9091c49f-c30a-5953-9194-7bbc8a0bf2c1","slug":"basis-for-recommendation-967","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f5a59071-8f28-47ec-ba2d-a7a700ee5c8f --><h4>Basis for recommendation</h4><!-- end field f5a59071-8f28-47ec-ba2d-a7a700ee5c8f -->","summary":null,"htmlStringContent":"<!-- begin item 9678856e-fe3a-4d52-a447-a7a700ee5b08 --><!-- begin field 392194d4-ab02-474a-9ea7-a7a700ee5c8f --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Atopic eczema in under 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2007</a>], the NICE technology appraisal <em>Frequency of application of topical corticosteroids for atopic eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2004</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SIGN, 2011</a>], the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practic</em>e [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>], the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>], and the manufacturer's summary of product characteristics for Betnovate cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>].</p><h5>Frequency of application</h5><ul><li>The recommendation on frequency of application of topical corticosteroids is based on a NICE Technology Appraisal that identified 10 randomized controlled trials (RCTs). The evidence suggested that, overall, there was little difference in effectiveness between once daily and more frequent application of topical corticosteroids, although a difference could not be ruled out [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2004</a>].<ul><li>A total of 10 RCTs compared once daily application with more frequent use of topical corticosteroids within the same potency group for the treatment of eczema. None of the studies found clear evidence that application more than once a day produced better overall clinical outcomes.</li><li>Taking into account evidence on cost-effectiveness, NICE recommends that topical corticosteroids should be prescribed 'for application only once or twice daily'.</li></ul></li><li>SIGN recommends that in people with atopic eczema topical corticosteroids should be applied once daily and if there is an inadequate response to increase to twice daily application [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SIGN, 2011</a>].</li><li>The recommendation to use topical corticosteroids in bursts of 3–7 days is based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>], and expert opinion in a narrative review <em>Atopic Dermatitis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Williams, 2005</a>].</li><li>The Australasian College of Dermatologists <em>Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Mooney, 2015</a>] advises that the phrase 'use sparingly' should be avoided as it is nonsensical and has no value, and it promotes inadequate use of topical corticosteroids. It recommends that people are advised to use topical steroids liberally and then carefully rubbed or massaged into inflamed skin, but to avoid very thick application.</li></ul><h5>Combining topical corticosteroids and emollient therapy</h5><ul><li>There is no evidence or consensus in the literature to help decide in which order preparations should be applied and the length of time people should wait before applying the second preparation. </li><li>The NICE guidance <em>Atopic eczema in under 12s: diagnosis and management</em> advises that products should be applied one at time with several minutes between applications where practical, and that the preferences of the child and parents or carers should determine which product should be applied first [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2007</a>].</li><li>A British Association for Dermatologists patient information leaflet advises that people should wait 20–30 minutes between the two treatments to avoid diluting the topical steroid and reducing its effectiveness, but does not advise which preparation should be applied first [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">BAD, 2019</a>]. </li><li>The manufacturer of Betnovate cream advises that adequate time should be allowed for absorption of the corticosteroid after each application before applying an emollient, but does not specify an amount of time to wait [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>].</li><li>The British National Formulary advises that mixing topical preparations on the skin should be avoided where possible and recommends that several minutes should elapse between application of different preparations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</li><li>In the expert opinion of previous external reviewers of this CKS topic, some recommend that the corticosteroid should be applied first. This is also a reasonable strategy, provided that sufficient time is allowed before the emollient is applied, to prevent dilution and unnecessary spreading of the corticosteroid. Waiting for 1 hour is suggested by some external reviewers.</li></ul><!-- end field 392194d4-ab02-474a-9ea7-a7a700ee5c8f --><!-- end item 9678856e-fe3a-4d52-a447-a7a700ee5b08 -->","subChapters":[]}]},{"id":"27853676-99e4-589d-86fa-ebd31c4ab957","slug":"quantity-to-prescribe","fullItemName":"Quantity to prescribe","depth":3,"htmlHeader":"<!-- begin field 7f44c550-9f9b-4d1e-bfaa-1bf5e0ac9300 --><h3>How much topical corticosteroid should I prescribe?</h3><!-- end field 7f44c550-9f9b-4d1e-bfaa-1bf5e0ac9300 -->","summary":null,"htmlStringContent":"<!-- begin item d3c0cd13-7615-4485-b699-7843c4f5e471 --><!-- begin field c2d034dd-17d5-4c94-babc-362646678900 --><ul><li>It is important that the appropriate quantity of topical corticosteroid is prescribed to avoid undertreatment. For suitable quantities of topical corticosteroid creams and ointments to prescribe, see Table 4.</li><li>For the weekly dose of topical corticosteroids unlikely to cause systemic adverse effects in adults, see Table 5.</li></ul><p><strong>Table 4.</strong> Suitable quantities of topical corticosteroids to prescribe (single daily application for 2 weeks).</p><table data-table-id=\"c458849a-9e5f-4ab8-94ee-acce014f00f4\"><thead><tr><th colspan=\"1\">Area of the body</th><th colspan=\"1\">Suitable quantity to prescribe</th></tr></thead><tbody><tr><td colspan=\"1\">Face and neck</td><td colspan=\"1\">15–30 g</td></tr><tr><td colspan=\"1\">Both hands</td><td colspan=\"1\">15–30 g</td></tr><tr><td colspan=\"1\">Scalp</td><td colspan=\"1\">15–30 g</td></tr><tr><td colspan=\"1\">Both arms</td><td colspan=\"1\">30–60 g</td></tr><tr><td colspan=\"1\">Both legs</td><td colspan=\"1\">100 g</td></tr><tr><td colspan=\"1\">Trunk</td><td colspan=\"1\">100 g</td></tr><tr><td colspan=\"1\">Groin and genitalia</td><td colspan=\"1\">15–30 g</td></tr><tr><td colspan=\"2\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>]</td></tr></tbody></table><p><strong>Table 5. </strong>Weekly dose of topical corticosteroids unlikely to cause systemic adverse effects in adults.</p><table data-table-id=\"b13ffd0d-a6ba-48e1-b4aa-acce014f00f4\"><thead><tr><th colspan=\"1\">Treatment period</th><th colspan=\"1\">Moderately potent</th><th colspan=\"1\">Potent</th><th colspan=\"1\">Very potent</th></tr></thead><tbody><tr><td colspan=\"1\">Less than 2 months</td><td colspan=\"1\">100g</td><td colspan=\"1\">50g</td><td colspan=\"1\">30g</td></tr><tr><td colspan=\"1\">2–6 months</td><td colspan=\"1\">50g</td><td colspan=\"1\">30g</td><td colspan=\"1\">15g</td></tr><tr><td colspan=\"1\">6–12 months</td><td colspan=\"1\">25g</td><td colspan=\"1\">15g</td><td colspan=\"1\">7.5g</td></tr><tr><td colspan=\"4\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Coulson, 1996</a>]</td></tr></tbody></table><!-- end field c2d034dd-17d5-4c94-babc-362646678900 --><!-- end item d3c0cd13-7615-4485-b699-7843c4f5e471 -->","subChapters":[{"id":"b1da7864-206b-5814-9b1c-53d4d5f4e9f2","slug":"basis-for-recommendation-51b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7a2eefb1-7b03-4886-8fa4-dfbfeab94949 --><h4>Basis for recommendation</h4><!-- end field 7a2eefb1-7b03-4886-8fa4-dfbfeab94949 -->","summary":null,"htmlStringContent":"<!-- begin item 51b60107-593c-44a6-81b4-492444d71ba6 --><!-- begin field 57cf5543-7fc4-4528-9e37-551ab486f562 --><p>These recommendations are based on the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>], and expert opinion in narrative reviews <em>Topical steroids for skin disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Coulson, 1996</a>] and <em>Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Beattie, 2003</a>].</p><ul><li>Undertreatment is a significant problem in primary care. It is caused by several factors, including under-prescribing and failure to use a sufficient quantity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Beattie, 2003</a>].</li></ul><!-- end field 57cf5543-7fc4-4528-9e37-551ab486f562 --><!-- end item 51b60107-593c-44a6-81b4-492444d71ba6 -->","subChapters":[]}]},{"id":"b8dd4a74-4c37-5a35-9c2e-4fa9a5450c65","slug":"withdrawal","fullItemName":"Withdrawal","depth":3,"htmlHeader":"<!-- begin field 8127402f-b4eb-4fad-82e8-168ff78fad09 --><h3>How should I withdraw or stop topical corticosteroid treatment?</h3><!-- end field 8127402f-b4eb-4fad-82e8-168ff78fad09 -->","summary":null,"htmlStringContent":"<!-- begin item d382c057-0b3a-4cdd-9add-dd674ab870a0 --><!-- begin field 41383c39-21a8-44cf-9e20-74b81624d0ac --><ul><li>Once a clinical response has been seen, withdraw long term topical corticosteroid treatment gradually in a stepwise manner. Abrupt withdrawal can cause a relapse or rebound of the condition being treated (for example psoriasis or eczema). </li><li>Consider the following options:<ul><li>Reduce the application frequency of the current corticosteroid. </li><li>Step down to a lower potency corticosteroid. </li><li>Use a lower potency corticosteroid together with other topical treatments (such as a vitamin D or coal tar preparation used in the treatment of psoriasis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/psoriasis/\">Psoriasis</a>). </li><li>Use a lower potency corticosteroid intermittently.</li></ul></li></ul><!-- end field 41383c39-21a8-44cf-9e20-74b81624d0ac --><!-- end item d382c057-0b3a-4cdd-9add-dd674ab870a0 -->","subChapters":[{"id":"ff709dc2-357c-51c9-ab65-769ac9eaf4a1","slug":"basis-for-recommendation-ed2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8042cb6b-f93e-4934-a850-1942c5811cb4 --><h4>Basis for recommendation</h4><!-- end field 8042cb6b-f93e-4934-a850-1942c5811cb4 -->","summary":null,"htmlStringContent":"<!-- begin item ed28ab69-7551-4809-9d41-4660aee127f6 --><!-- begin field 30acb69c-2031-4858-b4a7-848e74da3333 --><p>These recommendations are based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>]; the National Institute for Health and Care Excellence (NICE) guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2017</a>]; and expert opinion in narrative reviews <em>Topical steroids for skin disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Coulson, 1996</a>], <em>Guidelines of care for the management of psoriasis </em><em>and psoriatic arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>], and <em>Choosing topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>].</p><ul><li>Flares of eczema may occur if corticosteroids are stopped abruptly. Topical corticosteroids should be withdrawn gradually, decreasing the potency in a stepwise manner [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>].<ul><li>CKS is aware that some previous external reviewers of this CKS topic stated that gradual withdrawal is unnecessary, and may adversely influence adherence, especially when treating children.</li></ul></li></ul><!-- end field 30acb69c-2031-4858-b4a7-848e74da3333 --><!-- end item ed28ab69-7551-4809-9d41-4660aee127f6 -->","subChapters":[]}]},{"id":"4d939023-8262-53ec-a450-a5e22979a38a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field fe238719-963c-4538-a2a6-d4af3c4d20b4 --><h3>What contraindications and cautions are associated with topical corticosteroids?</h3><!-- end field fe238719-963c-4538-a2a6-d4af3c4d20b4 -->","summary":null,"htmlStringContent":"<!-- begin item 94f63eb2-e36d-4860-b8df-4d9f1b141365 --><!-- begin field 6b364b04-0f9a-460c-9793-6adb6f1a4712 --><ul><li><strong>Contraindications</strong><ul><li>Avoid prescribing topical corticosteroids in people with:<ul><li>Bacterial, fungal, or viral skin infections. </li><li>Rosacea. </li><li>Perioral dermatitis. </li><li>Acne vulgaris. </li><li>Anogenital pruritus. </li></ul></li><li>Topical corticosteroids should not be used indiscriminately for treating pruritus.</li></ul></li><li><strong>Cautions</strong><ul><li>Avoid prolonged use of corticosteroids, particularly on the face. </li><li>Potent corticosteroids should generally be avoided on the face and skin flexures. </li><li>Use topical corticosteroids with caution in the periocular area.</li></ul></li></ul><!-- end field 6b364b04-0f9a-460c-9793-6adb6f1a4712 --><!-- end item 94f63eb2-e36d-4860-b8df-4d9f1b141365 -->","subChapters":[{"id":"344b27f6-3b41-5b56-964c-13c449fc48db","slug":"basis-for-recommendation-a78","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d872a85e-f4a5-43bc-9b0c-07485cb315c5 --><h4>Basis for recommendation</h4><!-- end field d872a85e-f4a5-43bc-9b0c-07485cb315c5 -->","summary":null,"htmlStringContent":"<!-- begin item a789d059-af60-466c-9d9c-80eddc3dc311 --><!-- begin field 2ece0b1c-35eb-430a-a81b-234c63d33c2a --><p>These recommendations are based on the <em>British National Formulary</em> (BNF), the manufacturers' summaries of product characteristics for Betnovate cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>] and hydrocortisone 1% cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2020a</a>], and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SIGN, 2011</a>].</p><!-- end field 2ece0b1c-35eb-430a-a81b-234c63d33c2a --><!-- end item a789d059-af60-466c-9d9c-80eddc3dc311 -->","subChapters":[]}]},{"id":"c0c2b218-be76-55ec-8f33-9e60e6f4d7ac","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 96615706-b90b-426f-a6fb-45a9bd6d0ffa --><h3>Can I prescribe topical corticosteroids to a woman who is pregnant or breastfeeding?</h3><!-- end field 96615706-b90b-426f-a6fb-45a9bd6d0ffa -->","summary":null,"htmlStringContent":"<!-- begin item d0fc17b7-8c1c-4623-b522-450b27dfd174 --><!-- begin field db997193-c5d2-424a-a5a6-3098c9db6b4f --><h4>Pregnancy</h4><ul><li>Topical exposure to corticosteroids in pregnancy is expected to pose a low risk to the developing fetus.</li><li>However, factors affecting systemic absorption of the corticosteroid should be taken into account, including surface area, frequency of application, condition of skin, and the potency of preparation. </li></ul><h4>Breastfeeding</h4><ul><li>Topical corticosteroids pose a negligible risk to breastfeeding infants.</li><li>Before breastfeeding, the topical corticosteroid should be removed from all areas of the breast (especially nipples and areola areas) with warm water and reapplied after feeding — this is to prevent the infant’s mouth coming into direct contact with the topical corticosteroid. </li><li>When applied to the breast, the use of creams are preferred to ointments owing to ease of removal before breastfeeding — use the least potent preparations for the shortest duration where possible. <ul><li>Hydrocortisone (mild potency) and clobetasone (moderate potency) are preferred for application to the nipple and areola area – avoid application of high potency steroids to these areas. </li></ul></li></ul><!-- end field db997193-c5d2-424a-a5a6-3098c9db6b4f --><!-- end item d0fc17b7-8c1c-4623-b522-450b27dfd174 -->","subChapters":[{"id":"d795aec7-93dc-544c-8172-8854519da34a","slug":"basis-for-recommendation-a48","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d753dcac-b9df-4636-a360-3c216aae121d --><h4>Basis for recommendation</h4><!-- end field d753dcac-b9df-4636-a360-3c216aae121d -->","summary":null,"htmlStringContent":"<!-- begin item a48de57e-04f3-4be5-8d89-685c0e5faaa7 --><!-- begin field d9f67431-6bae-4b07-9dc4-05bd70513ca0 --><h5>Pregnancy</h5><ul><li>These recommendations are largely based on the UK Teratology Information Service (UKTIS) document <em>Use of topical corticosteroids in pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">UKTIS, 2016a</a>] and a Cochrane systematic review <em>Safety of topical corticosteroids in pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Chi, 2015</a>].<ul><li>Topical exposure to corticosteroids in pregnancy is expected to pose a low risk to the developing fetus. However, factors affecting systemic absorption of the corticosteroid should be taken into account, including surface area, frequency of application, condition of skin, and the potency of preparation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">UKTIS, 2016a</a>]. <ul><li>If topical use is extensive or significant systemic absorption is expected, information relating to systemic exposure of corticosteroids in pregnancy should be considered. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#pregnancy-breastfeeding\">Pregnancy and breastfeeding</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul></li><li>A Cochrane systematic review that assessed the effects of topical corticosteroids on pregnancy outcomes in five cohorts and nine case-control studies (n = 1,601,515) found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Chi, 2015</a>]:<ul><li>No association between maternal use of topical corticosteroids of any potency and an increase in adverse pregnancy outcomes, including mode of delivery, congenital abnormality, preterm delivery, fetal death, and low Apgar score. </li><li>A probable association between low birth weight and maternal use of potent to very potent topical corticosteroids, especially when the cumulative dosage of topical corticosteroids throughout the pregnancy is very large. </li></ul></li><li>The manufacturer of Betnovate cream advises that if it is used in pregnancy the minimum quantity should be used for the minimum duration [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>]. </li></ul></li></ul><h5>Breastfeeding</h5><ul><li>These recommendations are based on information published by the Specialist Pharmacy Service (SPS) document <em>Safety in lactation: topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SPS, 2016a</a>].</li></ul><!-- end field d9f67431-6bae-4b07-9dc4-05bd70513ca0 --><!-- end item a48de57e-04f3-4be5-8d89-685c0e5faaa7 -->","subChapters":[]}]},{"id":"0ffb49d3-cb51-5159-8cc5-224e22cee60f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ec56af0a-0758-4ee6-8771-27c4c7672867 --><h3>What are the adverse effects of topical corticosteroids?</h3><!-- end field ec56af0a-0758-4ee6-8771-27c4c7672867 -->","summary":null,"htmlStringContent":"<!-- begin item 9b2e08b5-68e7-4a5f-bb05-4cceffe15481 --><!-- begin field b12381a7-e7c1-48fd-aae9-82f5f5624250 --><ul><li><strong>When used correctly, topical corticosteroids rarely cause serious adverse effects.</strong></li><li><strong>The likelihood of adverse effects is directly related to:</strong><ul><li>Duration of treatment — long term treatment is likely to result in systemic absorption.</li><li>Area of the skin being treated — treating large areas of skin increases the risk of systemic absorption. </li><li>Condition of the skin — absorption is greatest in thin skin (for example, the face) and inflamed skin. </li><li>Potency of the topical corticosteroid — the greater the potency, the greater the risk of systemic absorption.</li><li>Occlusion — use of topical corticosteroids under occlusion increases the risk of systemic absorption.</li><li>Age — children (especially babies) and older people are more susceptible to adverse effects. </li></ul></li><li><strong>Local adverse effects are more common</strong> — they mostly occur on the face, in skin folds, and in areas that are treated over the long term. Local adverse effects include:<ul><li>Acne vulgaris.</li><li>Folliculitis. </li><li>Skin atrophy (thinning). </li><li>Telangiectasia.</li><li>Transient burning or stinging.</li><li>Permanent striae. </li><li>Allergic contact dermatitis.</li><li>Exacerbation of rosacea, perioral dermatitis, or tinea infections. </li><li>Skin depigmentation — usually reversible. </li><li>Excessive hair growth at the site of application (hypertrichosis). </li><li>Vasodilation. </li></ul></li><li><strong>Systemic adverse effects </strong>are rare, and more likely to occur when potent or very potent topical corticosteroids are used over a large surface area for a prolonged period (or when they are used under occlusion). Any of the adverse effects of oral corticosteroids may also occur with topical corticosteroids, especially in children, including: <ul><li>Adrenal suppression — for signs and symptoms of adrenal suppression, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/management/corticosteroids/#adrenal-insufficiency\">Adrenal insufficiency</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li><li>Cushing's syndrome.</li><li>Growth suppression.</li><li>Visual disturbance — if a person presents with symptoms such as blurred vision or other visual disturbances, consider referral to an ophthalmologist for evaluation of possible causes that may include cataract, glaucoma, or rare diseases such as central serous chorioretinopathy. </li></ul></li></ul><!-- end field b12381a7-e7c1-48fd-aae9-82f5f5624250 --><!-- end item 9b2e08b5-68e7-4a5f-bb05-4cceffe15481 -->","subChapters":[{"id":"0457b015-017e-54c3-8e7a-70a76eaaceda","slug":"basis-for-recommendation-b19","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 81466e82-2cf2-478e-9b2f-8136bdf9c821 --><h4>Basis for recommendation</h4><!-- end field 81466e82-2cf2-478e-9b2f-8136bdf9c821 -->","summary":null,"htmlStringContent":"<!-- begin item b19cd3bf-a8b4-45f7-ac1d-95d7798b6eef --><!-- begin field c284baa2-6143-4eff-9481-3d0262ed16e5 --><p>This information is largely based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practic</em>e [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>], expert opinion in a narrative review <em>Guidelines of care for the management of psoriasis and psoriatic arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>], the Australasian College of Dermatology consensus statement <em>Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Mooney, 2015</a>], expert opinion in a narrative review <em>Choosing topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>], and the summary of product characteristics for Betnovate cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>].</p><h5>Systemic adverse effects</h5><ul><li>An Australasian College of Dermatology consensus statement on the adverse effects of topical corticosteroids in paediatric eczema [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Mooney, 2015</a>] states that physiological hypothalamic-pituitary-adrenal (HPA) axis suppression can occur with very widespread and prolonged, or occlusive use of potent/superpotent topical corticosteroids. However, this recovers quickly, and clinically significant/pathological adrenal suppression is very rare in the treatment of paediatric eczema with topical corticosteroids. <ul><li>In a review of 16 topical corticosteroid trials that recorded HPA suppression, only one reported pathological adrenal suppression: five adult psoriasis patients who used more than 100 g clobetasol propionate a week for between 10 weeks to 18 months developed features of Cushing’s syndrome. </li><li>In the literature there are 25 paediatric case reports of HPA axis suppression. These children had mostly used super-potent topical steroids (clobetasol propionate) for 1–17 months for diaper eczema. </li></ul></li><li>While severe adverse effects of topical corticosteroids, such as Cushing syndrome and permanent skin atrophy, are well known, they rarely occur when they are used properly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Li, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Mooney, 2015</a>].</li><li>A systematic review and meta-analysis that assessed the risk of adrenal insufficiency with short term use of low to moderate potency topical corticosteroids for treatment of atopic dermatitis in children and adolescents found a low prevalence of adrenal insufficiency in people treated for a short term (2–4 weeks) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Davallow Ghajar, 2019</a>]. </li><li>Topically applied high and ultra high potency corticosteroids can be absorbed well enough to cause systemic side effects, including decreased growth rate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>].</li><li>There is a rare risk of central serous chorioretinopathy with local as well as systemic administration of corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MHRA, 2017</a>]. <ul><li>People should be advised to report any blurred vision or other visual disturbances during corticosteroid treatment.</li></ul></li></ul><!-- end field c284baa2-6143-4eff-9481-3d0262ed16e5 --><!-- end item b19cd3bf-a8b4-45f7-ac1d-95d7798b6eef -->","subChapters":[]}]},{"id":"25a5fcfd-be9d-5ca4-96a6-36612c380273","slug":"minimizing-adverse-effects","fullItemName":"Minimizing adverse effects","depth":3,"htmlHeader":"<!-- begin field c45b8c9b-277a-4de0-8056-4e82d827a609 --><h3>How should I minimize the risks of adverse effects in people using topical corticosteroids?</h3><!-- end field c45b8c9b-277a-4de0-8056-4e82d827a609 -->","summary":null,"htmlStringContent":"<!-- begin item 34acd612-b53c-4561-a460-b604590af3fb --><!-- begin field 411dd1a6-9156-42aa-b1ff-1b16763ec8e7 --><ul><li><strong>To minimize the adverse effects of topical corticosteroids:</strong><ul><li>Prescribe the least potent formulation that relieves the symptoms and advise the person to apply it thinly to affected areas, no more than twice daily. </li><li>Limit the <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#length-of-treatment\">length of treatment</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#quantity-to-prescribe\">quantity</a> used per week depending on the potency of the topical steroid, the indication, and the affected areas.  </li><li>Avoid prescribing potent corticosteroids for use on the face and skin flexures. <ul><li>If they are used in people with eczema, limit use to short periods only.</li></ul></li><li>Limit use of mild or moderate potency corticosteroids to a maximum of 2 weeks for people with psoriasis of the face, flexure, or genitals.</li><li>Avoid using occlusive dressings with potent or very potent topical corticosteroids.</li><li>Consider prescribing an appropriate quantity of an emollient for use alongside the topical corticosteroid. </li><li>If a topical corticosteroid is needed for maintenance therapy, consider intermittent use, with time periods when emollients are used on their own. </li></ul></li><li><strong>If the person is using large amounts of topical corticosteroid regularly, </strong>monitor them for signs of systemic adverse effects (such as adrenal suppression) and local adverse effects (such as thinning of the skin or striae). </li><li><strong>Monitor the height of children </strong>who are using large amounts of topical corticosteroid. Refer the child to a paediatrician if growth suppression is suspected. </li></ul><!-- end field 411dd1a6-9156-42aa-b1ff-1b16763ec8e7 --><!-- end item 34acd612-b53c-4561-a460-b604590af3fb -->","subChapters":[{"id":"7836c5ea-81fb-5907-9306-a7d5288d5d0f","slug":"basis-for-recommendation-c2b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 641f7886-1361-4348-b4b8-3335bbe2d7d7 --><h4>Basis for recommendation</h4><!-- end field 641f7886-1361-4348-b4b8-3335bbe2d7d7 -->","summary":null,"htmlStringContent":"<!-- begin item c2bf0824-b8b2-4445-b6e8-40b31ffb2066 --><!-- begin field 4ce6b9bc-2071-4b99-8076-848d16bb33b8 --><p>These recommendations are based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>]; the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>]; the National Institute for Health and Care Excellence (NICE) guidelines <em>Psoriasis: assessment and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2017</a>] and <em>Atopic eczema in under 12s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2007</a>]; the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SIGN, 2011</a>]; expert opinion in narrative reviews <em>Guidelines of care for the management of psoriasis and psoriatic arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>] and <em>Choosing topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>]; and the summary of product characteristics for Betnovate cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>].</p><h5>Monitoring growth of children</h5><ul><li>Topically applied high- and ultra-high potency corticosteroids can be absorbed well enough to cause systemic side effects, including decreased growth rate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>].</li><li>The recommendation to monitor growth in children is based on expert opinion in a narrative review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>] that recommends assessing growth of children using topical corticosteroids long term, and is what CKS considers good medical practice, as rarely, topical corticosteroids can cause system adverse effects, particularly in children. </li></ul><!-- end field 4ce6b9bc-2071-4b99-8076-848d16bb33b8 --><!-- end item c2bf0824-b8b2-4445-b6e8-40b31ffb2066 -->","subChapters":[]}]},{"id":"c10beb82-7271-5010-8979-8ece5d095145","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field ee95fdd0-be03-4781-86bc-7b1dfbd24cc9 --><h3>What information and advice should I give to a person receiving topical corticosteroids?</h3><!-- end field ee95fdd0-be03-4781-86bc-7b1dfbd24cc9 -->","summary":null,"htmlStringContent":"<!-- begin item c07af8fb-0a8a-48d7-a6d3-0fb200454f48 --><!-- begin field 9c018f1e-760d-448e-9ad8-5b7e5b83493e --><ul><li>Explain about the potency of each topical corticosteroid that has been prescribed, and if possible provide a written treatment plan, outlining the: <ul><li><strong>Quantity </strong>— explain <a class=\"topic-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/management/topical-treatment/#fingertip-units-ftus-for-adults\">Fingertip units (FTUs) for adults</a>, and advise the person to apply the topical corticosteroid thinly to the affected area. It should cover the inflamed skin even if it is excoriated. </li><li><strong>Duration of treatment  </strong>— advise the person not to use topical corticosteroids for longer than prescribed.</li><li><strong>Frequency </strong>— once daily (or sometimes twice daily). </li><li><strong>Location </strong>— people may be prescribed more than one topical corticosteroid, of different potencies, to be applied on different parts of the body. </li><li><strong>Method </strong>— topical corticosteroids should not be mixed with other topical preparations. Advise the person to:<ul><li>Wait 20–30 minutes between applications of the topical corticosteroid and emollient to avoid diluting the corticosteroid and reducing its effectiveness.</li><li>Rub gently into the skin — the corticosteroid should be applied gently in the direction of hair growth to prevent occlusion folliculitis. </li></ul></li></ul></li><li>Reassure the person that, when used correctly, topical corticosteroids rarely cause serious adverse effects. However, advise that they should seek medical review if they notice any adverse effects (such as thinning of the skin, striae, or acne vulgaris). </li><li>Advise the person to carry a steroid treatment card if they are receiving long term treatment (several weeks) with a potent or very potent topical corticosteroid. </li><li>Warn the person to keep away from fire or other naked flames (for example, candles, cigarettes) — if topical corticosteroids come into contact with dressings, clothing and bedding, the fabric can be easily ignited. </li><li>Remind the person not to use an out of date topical preparation as reuse of a microbially contaminated corticosteroid can be harmful. </li></ul><!-- end field 9c018f1e-760d-448e-9ad8-5b7e5b83493e --><!-- end item c07af8fb-0a8a-48d7-a6d3-0fb200454f48 -->","subChapters":[{"id":"684a5b04-9550-591d-ae22-cad6af2f725b","slug":"basis-for-recommendation-c7e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d60c3756-22aa-4821-bd46-1485e22d7816 --><h4>Basis for recommendation</h4><!-- end field d60c3756-22aa-4821-bd46-1485e22d7816 -->","summary":null,"htmlStringContent":"<!-- begin item c7e0edf0-0c2d-4a8d-8b26-bdb080f18578 --><!-- begin field abb9c1da-d444-4f60-b3cd-6debbacbf114 --><p>These recommendations are largely based on the National Prescribing Centre Bulletin <em>Using topical corticosteroids in general practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MeReC, 1999</a>]; the <em>British National Formulary</em> (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>]; the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">SIGN, 2011</a>]; expert opinion in narrative reviews <em>Guidelines of care for the management of psoriasis and psoriatic arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Menter, 2009</a>] and <em>Choosing topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Ference, 2009</a>]; a British Association of Dermatologists (BAD) patient information leaflet <em>Topical corticosteroids</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">BAD, 2019</a>]; and the summary of product characteristics for Betnovate cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>].</p><p><strong>Applying corticosteroids</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Mooney, 2015</a>]</p><ul><li>The Australian College of Dermatologists advises that there is no requirement: <ul><li>To use topical corticosteroids sparingly — an ample volume of cream should be applied that is sufficient to cover the entire affected area.</li><li>For intervals without therapy — the topical corticosteroid should be applied to all inflamed skin until eczema is cleared.  </li></ul></li><li>It also advises that the phrase 'use sparingly' should be avoided as it is nonsensical and has no value, and it promotes inadequate use of topical corticosteroids. It recommends that people are advised to use topical steroids liberally and then carefully rubbed or massaged into inflamed skin, but to avoid very thick application.</li><li>Underutilization of topical corticosteroids due to the widespread fear of side effects leads to worse outcomes for children with eczema in both the short and long term.</li></ul><p><strong>Timing of application of emollients and topical corticosteroids</strong></p><ul><li>There is no evidence or consensus in the literature to help decide in which order preparations should be applied and the length of time people should wait before applying the second preparation. </li><li>The NICE guidance <em>Atopic eczema in under 12s: diagnosis and management</em> advises that products should be applied one at a time with several minutes between applications where practical, and that the preferences of the child and parents or carers should determine which product should be applied first [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">NICE, 2007</a>].</li><li>A British Association for Dermatologists (BAD) patient information leaflet advises that people should wait 20–30 minutes between the two treatments to avoid diluting the topical steroid and reducing its effectiveness, but does not advise which preparation should be applied first [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">BAD, 2019</a>]. </li><li>The manufacturer of Betnovate cream advises that adequate time should be allowed for absorption of the corticosteroid after each application before applying an emollient, but does not specify an amount of time to wait [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">ABPI, 2019c</a>].</li><li>The British National Formulary recommends that mixing topical preparations on the skin should be avoided where possible; several minutes should elapse between application of different preparations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Joint Formulary Committee, 2020</a>].</li><li>In the expert opinion of previous external reviewers of this CKS topic, some recommend that the corticosteroid should be applied first. This is also a reasonable strategy, provided that sufficient time is allowed before the emollient is applied, to prevent dilution and unnecessary spreading of the corticosteroid. Waiting for 1 hour is suggested by some external reviewers.</li></ul><h5>Steroid treatment card</h5><ul><li>The recommendation to issue a steroid treatment card if the person is receiving long term treatment (for several weeks) with a potent or very potent topical corticosteroid, is based on what CKS considers to be good clinical practice.<ul><li>Most topical corticosteroids may, under certain circumstances, be absorbed in sufficient amounts to cause systemic adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">Brayfield, 2020</a>].</li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) advises that in addition to issuing a steroid treatment card to people on high dose inhaled corticosteroids, one may be issued to other people at high risk of systemic adverse effects at the discretion of the prescriber or pharmacist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/references/\">MHRA, 2006</a>].</li></ul></li></ul><!-- end field abb9c1da-d444-4f60-b3cd-6debbacbf114 --><!-- end item c7e0edf0-0c2d-4a8d-8b26-bdb080f18578 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}